In today’s briefing:
- Entegris (ENTG US) Promotion to S&P MidCap400
- Intel Former Board Members Warn Against Rumoured TSMC Takeover Of Intel Foundry
- Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility
- [ETP 2025/09] WTI Drops on Trade Tensions, Henry Hub Falls to Forecasts of Milder Temperatures
- IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025
- LNTH: 2025 Guidance Provided
- OMH: Backdrop of Industry Fundamentals, Positive Implications
Entegris (ENTG US) Promotion to S&P MidCap400
- Last night, the S&P announced that with the deletion of Arcadium Lithium (ALTM US) from the S&P Midcap 400, Entegris Inc (ENTG US) would replace it.
- Entegris is a company providing Materials Solutions and Purity Solutions to the semiconductor industry (they sell to circuit/memory cos, SPE mfrs, gas/chem cos, wafer growers, etc.
- Because of how this company is being added, it is a bit interesting. It will be effective Wednesday 5 March at the close with US$1.2bn to buy.
Intel Former Board Members Warn Against Rumoured TSMC Takeover Of Intel Foundry
- Four former, long term Intel board members yesterday warned against any plans to have TSMC take over Intel Foundry, their second time weighing in on the future of the company
- They posit that TSMC is under pressure from the US Administration with Taiwan security being used as a bargaining chip
- They’re not wrong in their assertions that it would be a terrible idea, both for the US and for TSMC, but these are days where anything can happen. Let’s see
Kestra Medical Technologies (KMTS): Medical Device IPO Story Easy to Digest Amidst Market Volatility
- Wearable defibrillator maker, Kestra Medical Technologies (KMTS US) is set to debut on Thursday (3/6) seeking a cash raise of up to $160 million and a valuation between $667m-$762.
- The deal is considered well-oversubscribed from continued 1-on-1 conversions and high-quality engagements.
- Given the financials and sector in which this company operates in and the strong backing (Bain Capital), we continue to believe this IPO will be well-received despite any market volatility.
[ETP 2025/09] WTI Drops on Trade Tensions, Henry Hub Falls to Forecasts of Milder Temperatures
- For the week ending 21/Feb, U.S. crude inventories dropped by 2.3m barrels, contradicting expectations of a 2.5m barrel build. Gasoline stockpiles unexpectedly rose, while distillate stocks surged more than expected.
- U.S. natural gas inventories fell by 261 Bcf for the week ending 21/Feb, lower than analyst expectations of a 276 Bcf drawdown. Inventories are 11.5% below the 5-year seasonal average.
- BP pivots back to fossil fuels, cutting renewables and reducing its quarterly buyback to USD 0.75 billion from USD 1.75 billion. President Trump revoked Chevron’s license to operate in Venezuela.
IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025
- On February 27, 2025, Imunon, Inc. (IMNN) announced financial results for 2024 and provided a business update.
- The company is currently finishing preparations to conduct a Phase 3 clinical trial of its lead development compound, IMNN-001, in the treatment of advanced ovarian cancer.
- We anticipate the 500-patient trial will initiate before the end of the first quarter of 2025.
LNTH: 2025 Guidance Provided
- Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.
- It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.
- The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.
OMH: Backdrop of Industry Fundamentals, Positive Implications
- The number of units in the company’s property management segment grew 23% sequentially in 3Q24 to 9,283 from 7,560 at the end of 2Q24.
- OMH attributes this to its expanded presence in the property management space.
- Its goal is to continue to increase the number of units under management, which Ohmyhome believes will contribute to growing Property Management segment and consolidated revenue, in part reflecting cross-promotional opportunities as a growth driver.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
